Aduro Biotech, Inc. (NASDAQ:ADRO) EVP Dirk G. Brockstedt sold 1,815 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $8.01, for a total transaction of $14,538.15. Following the completion of the transaction, the executive vice president now directly owns 75,533 shares of the company’s stock, valued at approximately $605,019.33. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Aduro Biotech, Inc. (NASDAQ ADRO) traded down $0.10 during trading hours on Friday, reaching $8.90. 117,478 shares of the company were exchanged, compared to its average volume of 501,562. Aduro Biotech, Inc. has a 52 week low of $6.01 and a 52 week high of $14.85.
Aduro Biotech (NASDAQ:ADRO) last posted its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.03). Aduro Biotech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The firm had revenue of $3.79 million for the quarter, compared to the consensus estimate of $4.04 million. During the same quarter in the prior year, the company earned ($0.54) earnings per share. The company’s quarterly revenue was up .0% compared to the same quarter last year. equities analysts anticipate that Aduro Biotech, Inc. will post -1.28 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/11/17/insider-selling-aduro-biotech-inc-adro-evp-sells-14538-15-in-stock.html.
A number of large investors have recently bought and sold shares of the stock. Harvard Management Co. Inc. bought a new stake in Aduro Biotech during the 3rd quarter valued at $69,418,000. Vanguard Group Inc. raised its holdings in Aduro Biotech by 5.4% in the 2nd quarter. Vanguard Group Inc. now owns 2,511,995 shares of the biotechnology company’s stock worth $28,637,000 after purchasing an additional 129,079 shares in the last quarter. State Street Corp raised its holdings in Aduro Biotech by 8.3% in the 2nd quarter. State Street Corp now owns 684,699 shares of the biotechnology company’s stock worth $7,808,000 after purchasing an additional 52,597 shares in the last quarter. Baillie Gifford & Co. raised its holdings in Aduro Biotech by 30.8% in the 3rd quarter. Baillie Gifford & Co. now owns 553,090 shares of the biotechnology company’s stock worth $5,891,000 after purchasing an additional 130,390 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in Aduro Biotech by 15.1% in the 2nd quarter. Northern Trust Corp now owns 453,115 shares of the biotechnology company’s stock worth $5,166,000 after purchasing an additional 59,490 shares in the last quarter. Institutional investors own 33.63% of the company’s stock.
A number of equities analysts have commented on ADRO shares. BidaskClub raised shares of Aduro Biotech from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Aduro Biotech in a research note on Wednesday, September 27th. Oppenheimer Holdings, Inc. began coverage on shares of Aduro Biotech in a research note on Monday, October 30th. They issued a “buy” rating and a $15.00 price target for the company. Canaccord Genuity set a $30.00 price objective on shares of Aduro Biotech and gave the company a “buy” rating in a research note on Thursday, August 3rd. Finally, Zacks Investment Research cut shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $19.14.
About Aduro Biotech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.